Laquinimod: Difference between revisions
CSV import |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 26: | Line 26: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Laquinimod.svg|Laquinimod chemical structure | |||
</gallery> | |||
Latest revision as of 00:32, 17 March 2025
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is currently being investigated for its potential use in treating multiple sclerosis and Huntington's disease.
Mechanism of Action[edit]
Laquinimod is believed to work by modulating the immune system, reducing inflammation and potentially even promoting neuroprotection. However, the exact mechanism of action is not fully understood.
Clinical Trials[edit]
Laquinimod has undergone several clinical trials to assess its safety and efficacy in treating multiple sclerosis and Huntington's disease.
Multiple Sclerosis[edit]
In clinical trials for multiple sclerosis, laquinimod has shown a reduction in the rate of relapse and a slowing of disease progression. However, it has not yet been approved for use in this condition.
Huntington's Disease[edit]
Clinical trials for Huntington's disease are ongoing. Preliminary results suggest that laquinimod may slow the progression of the disease, but further research is needed.
Side Effects[edit]
Common side effects of laquinimod include back pain, cough, and diarrhea. More serious side effects may include liver damage and severe allergic reactions.
